Skip to main content

Articles

Page 1 of 8

  1. Dendritic cell (DC) vaccines induce specific immune responses that can selectively eliminate target cells. In recent years, many studies have been conducted to explore DC vaccination in the treatment of hemato...

    Authors: Jifeng Yu, Hao Sun, Weijie Cao, Yongping Song and Zhongxing Jiang

    Citation: Experimental Hematology & Oncology 2022 11:3

    Content type: Review

    Published on:

  2. Tanshinone II A is an effective component extracted from Salvia miltiorrhiza and the roles of Tanshinone IIA in regulating the stemness of tumor cells remain unclear. This work aims to explore the roles and un...

    Authors: Xiaoman Li, Qi Jia, Yinyin Zhou, Xuan Jiang, Li Song, Yuanyuan Wu, Aiyun Wang, Wenxing Chen, Shijun Wang and Yin Lu

    Citation: Experimental Hematology & Oncology 2022 11:2

    Content type: Research

    Published on:

  3. Paroxysmal nocturnal hemoglobinuria is a clonal disease caused by PIG-A mutation of hematopoietic stem cells. At present, there is no suitable PNH animal model for basic research, therefore, it is urgent to estab...

    Authors: Yingying Chen, Hui Liu, Lijie Zeng, Liyan Li, Dan Lu, Zhaoyun Liu and Rong Fu

    Citation: Experimental Hematology & Oncology 2022 11:1

    Content type: Research

    Published on:

  4. Macrophages are heterogeneous cells that present as different functional phenotypes due to their plasticity. They can be classified into two categories, namely M1- and M2-like macrophages, which are involved i...

    Authors: Shuangli Zhu, Ming Yi, Yuze Wu, Bing Dong and Kongming Wu

    Citation: Experimental Hematology & Oncology 2021 10:60

    Content type: Review

    Published on:

  5. Selinexor, an oral selective inhibitor of nuclear export (SINE), was demonstrated to hinder the DNA damage repair (DDR) system by reducing DDR proteins while enhancing the killing of cancer cells by DDR-based ...

    Authors: Kyaw Z. Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Siqing Fu, Vivek Subbiah, David S. Hong, Timothy A. Yap, Jatin Shah, Denái R. Milton, Lacey McQuinn, Jing Gong, Yanyan Tran, Brett W. Carter, Rivka Colen…

    Citation: Experimental Hematology & Oncology 2021 10:59

    Content type: Letter to the Editor

    Published on:

  6. Interferon regulatory factor 4 (IRF4) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) an...

    Authors: Cosimo Cumbo, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Immacolata Redavid, Crescenzio Francesco Minervini, Nicoletta Coccaro, Giuseppina Tota, Alessandra Ricco, Elisa Parciante, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto and Francesco Albano

    Citation: Experimental Hematology & Oncology 2021 10:58

    Content type: Letter to the Editor

    Published on:

  7. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening syndrome that occurs in adult and pediatric patients after hematopoietic stem cell transplantation...

    Authors: Eleni Gavriilaki, Vincent T. Ho, Wilhelm Schwaeble, Thomas Dudler, Mohamed Daha, Teizo Fujita and Sonata Jodele

    Citation: Experimental Hematology & Oncology 2021 10:57

    Content type: Review

    Published on:

  8. Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which o...

    Authors: Yuze Wu, Ming Yi, Shuangli Zhu, Haiyong Wang and Kongming Wu

    Citation: Experimental Hematology & Oncology 2021 10:56

    Content type: Review

    Published on:

  9. Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a mul...

    Authors: Emma Rabinovich, Kith Pradhan, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Kira Gritsman, Mendel Goldfinger, Amit Verma and Ira Braunschweig

    Citation: Experimental Hematology & Oncology 2021 10:55

    Content type: Letter to the Editor

    Published on:

  10. Hepatocellular carcinoma (HCC) is a common malignancy in human. CD44 is a transmembrane glycoprotein which is frequently overexpressed in cancer of various origins. The function and mechanism of CD44 in HCC re...

    Authors: Jun Zhang, Xilin He, Yajie Wan, Honghong Zhang, Tao Tang, Meng Zhang, Shiyi Yu, Weiyong Zhao and Liming Chen

    Citation: Experimental Hematology & Oncology 2021 10:54

    Content type: Letter to the Editor

    Published on:

  11. Human gastrointestinal malignancies are highly heterogeneous cancers. Clinically, heterogeneity largely contributes to tumor progression and resistance to therapy. Heterogeneity within gastrointestinal cancers...

    Authors: Mei-Mei Li, Jun Yuan, Xin-Yuan Guan, Ning-Fang Ma and Ming Liu

    Citation: Experimental Hematology & Oncology 2021 10:53

    Content type: Review

    Published on:

  12. MET amplification plays an important role in the development of non-small-cell lung cancer (NSCLC) either de novo or in resistance to epidermal growth factor receptor tyrosine–kinase inhibitor (EGFR-TKI) settings...

    Authors: Lun-Xi Peng, Guang-Ling Jie, An-Na Li, Si-Yang Liu, Hao Sun, Mei-Mei Zheng, Jia-Ying Zhou, Jia-Tao Zhang, Xu-Chao Zhang, Qing Zhou, Wen-Zhao Zhong, Jin-Ji Yang, Hai-Yan Tu, Jian Su, Hong-Hong Yan and Yi-Long Wu

    Citation: Experimental Hematology & Oncology 2021 10:52

    Content type: Research

    Published on:

  13. Chromosomal translocations are the main etiological factor of hematologic malignancies. These translocations are generally the consequence of aberrant DNA double-strand break (DSB) repair. DSBs arise either ex...

    Authors: Mohsen Valikhani, Elahe Rahimian, Seyed Esmaeil Ahmadi, Rouzbeh Chegeni and Majid Safa

    Citation: Experimental Hematology & Oncology 2021 10:51

    Content type: Review

    Published on:

  14. The in vitro erythrocyte differentiation model remains a strong, clinically relevant tool to model erythroid development in normal and disease related hematopoiesis. This model also has application to developi...

    Authors: Matthew Cannon, Hannah Phillips, Sidney Smith, Shaneice Mitchell, Kristina Landes, Payal Desai, John Byrd and Rosa Lapalombella

    Citation: Experimental Hematology & Oncology 2021 10:50

    Content type: Letter to the Editor

    Published on:

  15. Bufadienolides derived from the skin of toads are often regarded as the main active components with antitumor effects. 19-Hydroxybufalin (19-HB) is a monomer of bufadienolides; however, its effects and underly...

    Authors: Wei Yu, Xiao Zhang, Wei Zhang, Minggang Xiong, Yuhan Lin, Ming Chang, Lin Xu, Yi Lu, Yun Liu and Jian Zhang

    Citation: Experimental Hematology & Oncology 2021 10:48

    Content type: Research

    Published on:

  16. Disease relapse after allogeneic stem cell transplantation is a major cause of treatment-related morbidity and mortality in patients with myeloproliferative neoplasms (MPNs). The cellular and molecular mechani...

    Authors: Haotian Zhang, Melissa Castiglione, Lei Zheng and Huichun Zhan

    Citation: Experimental Hematology & Oncology 2021 10:47

    Content type: Letter to the Editor

    Published on:

  17. Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatmen...

    Authors: Kaiqi Liu, Yan Li, Shaowei Qiu, Chunlin Zhou, Shuning Wei, Dong Lin, Guangji Zhang, Hui Wei, Ying Wang, Bingcheng Liu, Xiaoyuan Gong, Qiuyun Fang, Yang Song, Huijun Wang, Chengwen Li, Qinghua Li…

    Citation: Experimental Hematology & Oncology 2021 10:46

    Content type: Letter to the Editor

    Published on:

  18. We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later e...

    Authors: Yulei Wang, Li-Chun Lu, Yinghui Guan, Ming-Chih Ho, Shan Lu, Jessica Spahn and Chih-Hung Hsu

    Citation: Experimental Hematology & Oncology 2021 10:45

    Content type: Letter to the Editor

    Published on:

  19. Myelofibrosis (MF) may serve as a poor prognostic factor in myelodysplastic syndromes (MDS). This study explored the impact of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the outcome of M...

    Authors: Xiangzong Zeng, Li Xuan, Zhiping Fan, Yu Zhang, Ke Zhao, Ya Zhou, Jun Xu, Qifa Liu and Min Dai

    Citation: Experimental Hematology & Oncology 2021 10:44

    Content type: Research

    Published on:

  20. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has emerged as a deadliest global pandemic after its identification in December 2019 in Wuhan, China resulting in m...

    Authors: Syed Raza Ali Shah, Sherpa Dolkar, Jacob Mathew and Prakash Vishnu

    Citation: Experimental Hematology & Oncology 2021 10:42

    Content type: Case report

    Published on:

  21. Mantle cell lymphoma (MCL) is considered one of the most aggressive lymphoid tumors. However, it sometimes displays indolent behavior in patients and might not necessitate treatment at diagnosis; this has been...

    Authors: Panruo Jiang, Aakash Desai and Haige Ye

    Citation: Experimental Hematology & Oncology 2021 10:41

    Content type: Review

    Published on:

  22. Despite the advances in intensive chemotherapy regimens and targeted therapies, overall survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable chemotherapy resistance and high rela...

    Authors: Yiyi Yao, Fenglin Li, Jiansong Huang, Jie Jin and Huafeng Wang

    Citation: Experimental Hematology & Oncology 2021 10:39

    Content type: Review

    Published on:

  23. Common variable immunodeficiency (CVID) was a kind of primary immunodeficiency disorders with heterogeneous phenotype and genotype. Lipopolysaccharide-responsive and beige-like anchor (LRBA) mutation was ident...

    Authors: Yanling Ren, Feng Xiao, Fei Cheng, Xin Huang, Jianhu Li, Xiaogang Wang, Wei Lang, Xinping Zhou, Jianping Lan and Hongyan Tong

    Citation: Experimental Hematology & Oncology 2021 10:38

    Content type: Letter to the Editor

    Published on:

  24. Lynch syndrome is one of the most common hereditary cancer syndromes and is characterized by the development of many cancers, such as colorectal cancer (CRC), endometrial cancer, ovarian cancer, stomach cancer...

    Authors: Xi Li, Guodong Liu and Wei Wu

    Citation: Experimental Hematology & Oncology 2021 10:37

    Content type: Review

    Published on:

  25. Tumor-associated macrophages (TAMs) promote key processes in the modulation of tumor microenvironment (TME). However, the clinical significance of heterogeneous subpopulations of TAMs in hepatocellular carcino...

    Authors: Nan Xiao, Xiaodong Zhu, Kangshuai Li, Yifan Chen, Xuefeng Liu, Bin Xu, Ming Lei, Jiejie Xu and Hui-Chuan Sun

    Citation: Experimental Hematology & Oncology 2021 10:36

    Content type: Research

    Published on:

  26. N6-methyladenosine (m6A) modification, as the most abundant RNA modification, widely participates in the physiological process and is involved in multiple disease progression, especially cancer. YTH N6-methyladen...

    Authors: Xiangyuan Luo, Mengdie Cao, Fan Gao and Xingxing He

    Citation: Experimental Hematology & Oncology 2021 10:35

    Content type: Research

    Published on:

  27. The 2016 World Health Organization (WHO) classification introduced nodal lymphomas of T follicular helper (Tfh) cell origin, such as angioimmunoblastic T-cell lymphoma (AITL), follicular peripheral T-cell lymp...

    Authors: Sang Eun Yoon, Junhun Cho, Yeon Jeong Kim, Young Hyeh Ko, Woong-Yang Park, Seok Jin Kim and Won Seog Kim

    Citation: Experimental Hematology & Oncology 2021 10:33

    Content type: Research

    Published on:

  28. Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a very rare lymphoma with an aggressive clinical course and a dismal outcome. The prognosis is linked to a pronounced resistance to chemotherapy and ...

    Authors: Sophie Voruz, Laurence de Leval and Anne Cairoli

    Citation: Experimental Hematology & Oncology 2021 10:32

    Content type: Letter to the Editor

    Published on:

  29. Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME). However, their contribution to the immunosuppressive status of the TME remains unclear.

    Authors: Linbang Wang, Tao He, Jingkun Liu, Jiaojiao Tai, Bing Wang, Zhiyu Chen and Zhengxue Quan

    Citation: Experimental Hematology & Oncology 2021 10:31

    Content type: Research

    Published on:

  30. Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractor...

    Authors: Yoshiko Okita, Rieko Kano-Fujiwara, Shin-Ichi Nakatsuka, Keiichiro Honma and Manabu Kinoshita

    Citation: Experimental Hematology & Oncology 2021 10:29

    Content type: Letter to the Editor

    Published on:

  31. The evasion of apoptosis through dysregulated Bcl-2 family members is a hallmark of leukaemia stem cells (LSCs) in acute myeloid leukaemia (AML). Therefore, targeting Bcl-2 with venetoclax has been suggested a...

    Authors: Hyunsoo Cho, Ji Eun Jang, Ju-In Eom, Hoi-Kyung Jeung, Haerim Chung, Jin Seok Kim, June-Won Cheong and Yoo Hong Min

    Citation: Experimental Hematology & Oncology 2021 10:28

    Content type: Research

    Published on:

  32. The receptor tyrosine kinase FLT3 with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) is a poor prognostic factor; however, the prognostic significance of missense mutation in the tyrosin...

    Authors: Wei Guan, Lei Zhou, Yan Li, Erna Yang, Yangyang Liu, Na Lv, Lin Fu, Yi Ding, Nan Wang, Nan Fang, Qian Liu, Binan Wang, Fuwei Li, Juan Zhang, Maoquan Wang, Lili Wang…

    Citation: Experimental Hematology & Oncology 2021 10:27

    Content type: Research

    Published on:

  33. Aberrant DNA methylation is often related to the diagnosis, prognosis, and therapeutic response of acute myeloid leukemia (AML); however, relevant studies on the relationship between bone marrow myeloblast per...

    Authors: Erna Yang, Desheng Gong, Wei Guan, Jieying Li, Xuefeng Gao, Yonghui Li and Li Yu

    Citation: Experimental Hematology & Oncology 2021 10:26

    Content type: Letter to the Editor

    Published on:

  34. Proprotein convertase subtilisin/kexin type 9 (PCSK9), one of the key enzymes in the process of lipid transport, is involved in the disease progression of various types of tumors. This article is to study the ...

    Authors: Shi-Zhe Zhang, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Xue-Feng Liu, Hui-Chuan Sun and Zhao-You Tang

    Citation: Experimental Hematology & Oncology 2021 10:25

    Content type: Research

    Published on:

  35. BM-MSCs play an important role in cancer development through the release of cytokines or exosomes. Studies have shown that extracellular exosomes derived from BM-MSCs are a key pro-invasive factor. However, ho...

    Authors: Tianxin Lyu, Yinuo Wang, Ding Li, Hui Yang, Bin Qin, Wenli Zhang, Zhiyue Li, Cheng Cheng, Binglei Zhang, Rongqun Guo and Yongping Song

    Citation: Experimental Hematology & Oncology 2021 10:24

    Content type: Research

    Published on:

  36. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic m...

    Authors: Huijun Huang, Wenjun Zhang, Wenyu Cai, Jinqin Liu, Huijun Wang, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Gang Huang, Robert Peter Gale and Zhijian Xiao

    Citation: Experimental Hematology & Oncology 2021 10:23

    Content type: Letter to the Editor

    Published on:

  37. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli

    Citation: Experimental Hematology & Oncology 2021 10:22

    Content type: Correction

    Published on:

    The original article was published in Experimental Hematology & Oncology 2021 10:14

  38. Tumor mutation burden (TMB) as estimated by cancer gene panels (CGPs) has been confirmed to be associated with prognosis and is effective in predicting clinical benefit from immune checkpoint blockade (ICB) in...

    Authors: Cunte Chen, Sichu Liu, Xinmiao Jiang, Ling Huang, Feili Chen, Xiaojun Wei, Hanguo Guo, Yang Shao, Yangqiu Li and Wenyu Li

    Citation: Experimental Hematology & Oncology 2021 10:20

    Content type: Research

    Published on:

  39. Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. Howe...

    Authors: Mengke Niu, Ming Yi, Ning Li, Suxia Luo and Kongming Wu

    Citation: Experimental Hematology & Oncology 2021 10:18

    Content type: Review

    Published on:

  40. Hepatocellular carcinoma (HCC) is one of the common cancers that are very aggressive. The secreted cytokine transforming growth factor-β (TGF-β) promotes cancer metastasis by multiple mechanisms such as epithe...

    Authors: Shu Yang, Hongying Zhang, Hua Yang, Jin Zhang, Jiao Wang, Ting Luo, Yangfu Jiang and Hui Hua

    Citation: Experimental Hematology & Oncology 2021 10:17

    Content type: Research

    Published on:

  41. Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the...

    Authors: Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li and Lijuan Chen

    Citation: Experimental Hematology & Oncology 2021 10:16

    Content type: Letter to the Editor

    Published on:

  42. Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belino...

    Authors: Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng and Francine M. Foss

    Citation: Experimental Hematology & Oncology 2021 10:15

    Content type: Research

    Published on:

  43. The aim of the present study was to evaluate the circulating T regulatory cells (Tregs) in patients undergoing extracorporeal photopheresis (ECP) for the prevention of chronic graft-versus-host disease (GvHD) ...

    Authors: Roberto Crocchiolo, Clara Cesana, Debora Girgenti, Giambattista Bertani, Claudia Barba, Giuseppa Liga, Ursula Ferri, Lara Crucitti, Giovanni Grillo, Silvano Rossini and Roberto Cairoli

    Citation: Experimental Hematology & Oncology 2021 10:14

    Content type: Letter to the Editor

    Published on:

    The Correction to this article has been published in Experimental Hematology & Oncology 2021 10:22

Annual Journal Metrics